SFDA Approves Tzield As First Drug To Delay Onset Of Type 1 Diabetes In Patients Aged Eight And Older

The Saudi Food and Drug Authority (SFDA) has approved Tzield (teplizumab) for delaying Stage 3 type 1 diabetes in adults and children aged 8 and older with Stage 2 type 1 diabetes. This approval marks the first of its kind for this medical indication, highlighting a significant advancement in diabetes treatment options.

Tzield is a monoclonal antibody that targets CD3, an antigen on T lymphocytes. By binding to these cells, it helps inhibit their activity or reduce their number. This action aids in restoring immune balance and delaying disease progression. The drug is administered as a daily intravenous infusion over 14 consecutive days without repetition.

Clinical trials have shown that Tzield significantly delays the onset of Stage 3 type 1 diabetes compared to placebo in high-risk individuals. These individuals had positive autoantibodies but had not yet developed symptoms. The median time to diagnosis was extended by 24.6 months for those receiving Tzield compared to those given a placebo.

The SFDA's decision followed a comprehensive evaluation of the drug's efficacy, safety, and quality according to regulatory standards. The approval process included reviewing clinical trial data that demonstrated Tzield's effectiveness in delaying disease progression.

Common adverse events reported during clinical studies included lymphopenia, rash, leukopenia, and headache. There are also warnings about potential risks such as cytokine release syndrome, infections, lymphopenia, and hypersensitivity reactions associated with the drug.

This approval underscores the SFDA’s dedication to expanding therapeutic options and fostering research and innovation within Saudi Arabia's healthcare sector. It aligns with the Health Sector Transformation Program under Saudi Vision 2030, aiming to enhance patient care through novel treatments.

Tzield is specifically for patients with confirmed Stage 2 type 1 diabetes. These patients exhibit at least two positive pancreatic islet autoantibodies and abnormal blood glucose levels without having type 2 diabetes. This targeted approach ensures that only those who will benefit most receive the treatment.

The SFDA’s endorsement of Tzield reflects its commitment to improving patient quality of life by offering innovative treatments. This initiative supports the development of a sustainable healthcare system in line with national health objectives.

With inputs from SPA